Why the study?
Dual antiplatelet therapy in ACS increases bleeding risk, a complication with significant morbidity and mortality requiring decisive clinical management across follow-up.
This review provides a clinical perspective on managing and reducing bleeding risk in ACS patients receiving dual antiplatelet therapy.
Offers clinicians a patient-tailored strategy for bleeding management in ACS on DAPT; leaves open prospective validation of tailored approaches.
Inhibition of platelet function by means of dual antiplatelet therapy (DAPT) is the cornerstone of treatment of acute coronary syndrome (ACS). While preventing ischemic recurrences, inhibition of platelet function is clearly associated with an increased bleeding risk, a feared complication that may lead to significant morbidity and mortality. Since bleeding risk management is intrinsically associated with therapeutic adjustments undertaken during the whole clinical history of patients with acute coronary syndrome, single decisions taken from the very first day to years of follow-up might be decisive. This review aims at providing a clinically oriented, patient-tailored approach in reducing the risk and manage bleeding complications in ACS patients treated with DAPT. The steps in clinical decision making from the day of ACS to follow-up are analyzed. New treatment strategies to enhance the safety of DAPT are also described.
No takes yet. Share an insight, caveat, or question.
Tersalvi et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: